Search
for
Sort by
Research 571–600 of 575
- Molecular and cellular mechanisms of natural cosmetics and medical treatment in skin-antiaging: A review article
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
- Treatment of Lichen Planopilaris and Frontal Fibrosing Alopecia: A Retrospective, Real-Life Analysis in a Tertiary Center in Germany
- Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children
- Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up
- Association of JAK 1 and JAK 2 gene polymorphism with alopecia areata risk: a case–control genetic study
- Janus Kinase inhibitors in dermatology: a review
- Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Personalized Medicine in the Field of Inflammatory Skin Disorders
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Efficacy and Potential Mechanisms of Naringin in Atopic Dermatitis
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Down‐regulation of Shh in the hair follicles of mice during chemotherapy‐induced hair loss is mediated by the JAK / STAT1 signaling pathway
- JAK1 Signaling Is Involved in the Induction of Mechanical Alloknesis in Atopic Dermatitis
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Integrative analysis of rare copy number variants and gene expression data in alopecia areata implicates an aetiological role for autophagy
- Association between genetically predicted rheumatoid arthritis and alopecia areata: a two-sample Mendelian randomization study
- JAK-centric explainable few-shot gene-expression diagnosis framework for alopecia via MultiPLIER priors and relation-style set-to-set comparison
- Effect of Topical Gel Administration of Secretome Hypoxia Mesenchymal Stem Cells (SH-MSCs) on IL-10 and TNF- α Gene Expression (In Vivo Experimental Study in Male Rats of Wistar Strains Model of Fluconazole-Induced Alopecia)
- Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Under Development JAK Inhibitors for Dermatologic Diseases
- Alopecia Areata: Current Review
- Jak inhibitors in the treatment of alopecia areata - a literature review